N/A
Completed N=509
Prospective, Open-label Tolerability and Safety Monitoring Study of Novantrone in a Selected Cohort of Multiple Sclerosis Patients
Source: ClinicalTrials.gov NCT00262314 ↗Enrolled (actual)
509
Serious AEs
20.0%
Results posted
Jun 2010
Primary outcomePrimary: Congestive Heart Failure (Treatment Phase) — 6 participants
Summary
The overall objective of this study is to collect data relevant to the tolerability of Novantrone® therapy in patients with multiple sclerosis (MS) using dosing and monitoring recommendations specified in the package insert.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Congestive Heart Failure (Treatment Phase) |
6 | — |
| PRIMARY Congestive Heart Failure (Annual Follow-Up Phase) |
4 | — |
| PRIMARY Left Ventricular Ejection Fraction (Treatment Phase) |
27 | — |
| PRIMARY Left Ventricular Ejection Fraction (Annual Follow-Up Phase) |
14 | — |
| PRIMARY Serious Infections (Treatment Phase) |
50 | — |
| PRIMARY Serious Infections (Annual Follow-Up Phase) |
— | — |
| PRIMARY IV Antibiotics (Individual Drugs Unspecified) Utilized Due to Serious Infection (Treatment Phase) |
40 | — |
| PRIMARY IV Antibiotics (Individual Drugs Unspecified) Utilized Due To Serious Infection (Annual Follow-Up Phase) |
— | — |
| PRIMARY Severe Neutropenia (Treatment Phase) |
9 | — |
| PRIMARY Severe Neutropenia (Annual Follow-Up Phase) |
— | — |
| PRIMARY Clinical Relapses (Treatment Phase) |
185 | — |
| PRIMARY Clinical Relapses (Annual Follow-Up Phase) |
60 | — |
| PRIMARY Symptomatic CHF, Left Ventricular Ejection Fraction - Prior to Each Dose • Serious Infections, IV Antibiotics, or Assoc w/ Severe Neutropenia-evaluated. Novantrone Admin - Per PI • SAE, Clinical Relapses |
— | — |
Eligibility Criteria
Inclusion Criteria
- To be eligible for inclusion into this study, the subjects must fulfill all of the following criteria:
- Platelet count >100,000 cells/µL
- Granulocyte count > 2000 cells/µL
- Age 18-65 years
- Negative pregnancy test for female patients who are biologically capable of becoming pregnant, even if they are taking birth control
- For patients of reproductive age, agreement to practice effective contraception throughout the study and for 6 months following the last administration of Novantrone®
- Signed Inform Consent.
Exclusion Criteria
- To be eligible for inclusion in this study the subjects must not meet any of the following criteria:
- Presence of cardiac risk factors:
- History of congestive heart failure
- LVEF 2x upper limits of normal
- Severe untreated infection (including current urinary tract infection)
- Nursing or pregnant women)
Data sourced from ClinicalTrials.gov (NCT00262314). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.